Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis

@article{Park2013SevereDA,
  title={Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis},
  author={Sang Hyoung Park and Suk Kyun Yang and Seung-Mo Hong and Soo-Kyung Park and Jong Wook Kim and Hyo Jeong Lee and Dong-Hoon Yang and Kee Wook Jung and Kyung-Jo Kim and Byong Duk Ye and Jeong-Sik Byeon and S J Myung and Jin-Ho Kim},
  journal={Digestive Diseases and Sciences},
  year={2013},
  volume={58},
  pages={3592-3599}
}

• Sang Hyoung Park, Suk Kyun Yang, +10 authors Jin-Ho Kim
• Published 2013 in Digestive Diseases and Sciences
• DOI:10.1007/s10620-013-2828-1

The role of infliximab in the treatment of patients with ulcerative colitis (UC) in Asia is still unclear. The aim of this study was to evaluate the clinical outcomes of infliximab therapy in Korean UC patients, including efficacy and predictors of response. Patients who received infliximab induction therapy for moderate to severe UC at Asan Medical Center were retrospectively analyzed. The demographic characteristics of these patients and their clinical outcomes following infliximab therapy… CONTINUE READING

Save to Library

Create Alert

Cite

View on Springer